ArticleJournal of cancer survivorship : research and practice2026
Increased risk of fracture among breast cancer patients: a nationwide retrospective cohort study.
Article in Journal of cancer survivorship : research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk of osteoporosis and fracture among patients with breast cancer: a systematic review and meta-analysis of cohort studies.Frontiers in oncology · 2026Pooled it
- Association Between Endocrine Therapy and Fracture Risk in Women with Breast Cancer in Germany-A Retrospective Cohort Study.Current oncology (Toronto, Ont.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBreast cancer treatments contribute to bone loss and increase fracture risk, with effects varying by age and menopausal status. Previous studies lacked comparisons with the general population and analyses by treatment and age groups. This study evaluated fracture risk in breast cancer patients compared to a matched control group, considering risk factors, age, and treatments.
methodsThis retrospective cohort study using the Korean National Health Insurance System database included 104,177 breast cancer patients and 312,531 matched controls. Fracture incidences (any, vertebral, hip, and other) by age and treatment type was assessed using Fine-Gray competing risk models.
resultsDuring the mean follow-up of 7.21 years after breast cancer diagnosis, breast cancer patients aged 50 years and younger had a higher risk of any fracture (sub-distribution hazard ratio [sHR], 1.33; 95% confidence interval [95% CI], 1.24-1.42) and vertebral fracture (sHR, 1.33; 95% CI, 1.13-1.56) compared to the matched control group. Patients aged 65 years and older had a lower risk of any fracture (sHR, 0.91; 95% CI 0.84-0.98) and vertebral fracture (sHR, 0.83; 95% CI, 0.73-0.93). Compared to patients without specified treatments, those who received anthracycline (sHR, 1.21; 95% CI, 1.15-1.28) and aromatase inhibitors (sHR, 1.16; 95% CI, 1.09-1.23) had an increased risk of fracture; and those who were given tamoxifen had a decreased risk (sHR, 0.92; 95% CI, 0.86-0.98).
conclusionsBreast cancer patients had slightly higher fracture risk, primarily in younger patients. Emphasizing osteoporosis prevention and treatment, especially in younger populations or those who have received treatments associated with an increased risk of fracture, is necessary to reduce fracture risk.
Indexed as
Identifiers
41652295What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.